Some drugs, such as larotrectinib and entrectinib for patients with TRK gene fusions and pembrolizumab for patients with MSI-high status or dMMR or high TMB, represent a treatment option also for metastatic TNBC, thanks to tumour agnostic approval, an approach based on cancer’s genetic and molecular features without regard to the tumour type. The gene discussed is NTRK1; the disease is cancer.